Drugs moving into the clinic: 19

By Mike Nagle

- Last updated on GMT

The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
SponsorNameIndication Mechanism
Multiple Myeloma Research Consortium (MMRC) & Emory UniversityTipifarnib and Velcade (bortezomib)Oncology - relapsed or refractory multiple myeloma First-in-clinic farnesyl transferase inhibitor plus Ortho Biotech / Janssen Cilag's proteasome inhibitor
Novo Nordisk & Neose TechnologiesGlycoPEGylated Factor VIIa Cardiovascular - reduce bleeding in haemophiliaLong-acting version of NovoSeven Coagulation Factor VIIa
StemCells IncHuCNS-SCCNS - infantile and late infantile neuronal ceroid lipofuscinosis aka Batten disease purified human neural stem cells
CoMentisCTS-21166CNS- Alzheimer's diseaseoral small molecule beta-secretase inhibitor
IntercellVaccine formulated with IC31Anti-infectives & vaccines - influenza Adjuvant designed to increase T-cell response and enable cross-strain protection
OSI Pharma- ceuticals OSI-906 Oncology - colorectal, prostate, non-small cell lung, breast and ovarian cancersOral inhibitor of the insulin-like growth factor-1 receptor (IGF-1R)
Collegium Pharma- ceuticalCOL-003Painsustained release opioid formulation using oral delivery technology, DETERx, to act as an abuse deterrent
Altus Pharma- ceuticalsALTU-237Hyperoxalurias and the possible prevention of recurrent kidney stones Orally-delivered crystalline formulation of an oxalate-degrading enzyme

Related topics: Preclinical Research

Related news

Show more